Название продукции:(R)-3-Boc-AMinopiperidine
IUPAC Name:tert-butyl N-[(3R)-piperidin-3-yl]carbamate
- CAS：309956-78-3
- Молекулярная формула：C10H20N2O2
- Чистота：97%
- Номер в каталоге：CM101941
- Молекулярная масса：200.28
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:309956-78-3
- Молекулярная формула:C10H20N2O2
- Точка плавления:-
- Smiles-код:O=C(N[C@H]1CNCCC1)OC(C)(C)C
- Плотность:
- Номер в каталоге:CM101941
- Молекулярная масса:200.28
- Точка кипения:
- Номер Mdl:MFCD03093382
- Хранение:Store at room temperature.
Category Infos
- Piperidines
- Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.
- Piperidine,Piperidine Price
- if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.
Column Infos
- BMF-219
- Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.
- JNT-517
- Jnana Therapeutics announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19, is being evaluated as a potential first-in-class oral treatment for PKU across all ages and genotypes. Based on these positive mid-term results, Jnana has adjusted its phase 1b clinical trial design to support the critical phase 3 clinical trial of JNT-517 starting in the first half of 2025.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Поиск 
+86 21 5895 0110 
